Latest Insider Transactions at Arcus Biosciences, Inc. (RCUS)
This section provides a real-time view of insider transactions for Arcus Biosciences, Inc. (RCUS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Arcus Biosciences, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Arcus Biosciences, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 19
2021
|
Terry J Rosen Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+16.11%
|
-
|
|
Jan 19
2021
|
Carolyn C. Tang General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
12,538
+38.67%
|
-
|
|
Dec 17
2020
|
Andrew J Perlman Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+50.0%
|
-
|
|
Dec 16
2020
|
William Grossman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,117
-23.94%
|
$65,627
$31.35 P/Share
|
|
Oct 13
2020
|
Juan C. Jaen President |
SELL
Bona fide gift
|
Indirect |
1,207,000
-43.43%
|
-
|
|
Oct 02
2020
|
William Grossman Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+49.85%
|
-
|
|
Mar 19
2018
|
Column Group Ii, LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
3,540,850
+34.28%
|
-
|
|
Mar 19
2018
|
Gv 2017 Gp, L.L.C. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,924,474
+50.0%
|
-
|
|
Mar 19
2018
|
Gv 2016 Gp, L.L.C. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,125,312
+50.0%
|
-
|